Last reviewed · How we verify
dose adaptation of Enoxaparin
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis and treatment, Acute coronary syndrome, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | dose adaptation of Enoxaparin |
|---|---|
| Sponsor | French Cardiology Society |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin works by potentiating antithrombin III, a natural anticoagulant, to inactivate clotting factors Xa and IIa. Dose adaptation refers to adjusting the enoxaparin dose based on patient factors such as renal function, body weight, and clinical indication to optimize anticoagulation efficacy while minimizing bleeding risk. This approach, as recommended by the French Cardiology Society, ensures therapeutic drug levels are maintained across diverse patient populations.
Approved indications
- Venous thromboembolism prophylaxis and treatment
- Acute coronary syndrome
- Atrial fibrillation for stroke prevention
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
- Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dose adaptation of Enoxaparin CI brief — competitive landscape report
- dose adaptation of Enoxaparin updates RSS · CI watch RSS
- French Cardiology Society portfolio CI